German Federal Joint Committee recognises added benefit of once-daily LIXIANA® (edoxaban) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation

DAIICHI SANKYO EUROPE GmbH: Munich (ots/PRNewswire) – Daiichi Sankyo Europe GmbH (hereafter, Daiichi Sankyo) today announced that the German public health agency, The Federal Joint Committee (Gemeinsamer Bundesausschuss – G-BA), has granted an indication of a minor additional …

Das könnte Sie interessieren

Daiichi Sankyo Launches Once-Daily LIXIANA? Sales Alliance in Europe
Daiichi Sankyo to Present Findings From New Subgroup Analyses of Once-Daily LIXIANA® (edoxaban) in NVAF and VTE at ACC’s 65th Annual Scientific Session